雍禾醫療(02279.HK)盈喜:預計上半年淨利潤不少於2500萬元
格隆匯7月29日丨雍禾醫療(02279.HK)發佈公吿,截至2025年6月30日止六個月(“有關期間”),集團估計於有關期間的淨利潤不少於人民幣2500萬元,而2024年同期的虧損為人民幣1.386億元。
董事會認為集團盈利能力提升主要歸因於以下原因:(i)集團通過優化門店網絡佈局,有效將資源聚焦核心門店,顯著提升院部運營效率;此外,持續升級自研連鎖醫療管理系統“禾帆”,融入企業AI知識庫引擎並形成智能化解決方案。上述舉措幫助集團實現對其主營業務增效、質控、降本的精細化管理,帶動毛利率顯著增長。預計於有關期間,集團毛利率增長4.5至5.5個百分點。
(ii)集團通過管理模型重構及營銷投放精細化管理,顯著提升獲客轉化率及投入產出比;同時進行組織架構調整,提升人力資源配置效率,進一步優化成本結構。預計於有關期間,銷售費用率和管理費用率將分別下降6.0%至8.0%以及2.0%至3.0%。這一系列舉措亦為公司實現扭虧為盈以及未來長期可持續盈利奠定堅實基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.